Atrial Fibrillation
Conditions
Brief summary
Atrial fibrillation is the major cause of acute ischemic stroke. The risk of stroke was shown to decline by oral anticoagulant therapy. The investigators intended to evaluate appropriate use of anticoagulants in non-valvular AF patients.
Detailed description
Atrial fibrillation, the most common sustained arrhythmia, is the major cause of acute ischemic stroke. The prognosis of ischemic stroke associated with atrial fibrillation (AF) tends to have a worse prognosis for recovery compared with other ischemic stroke subtypes. The risk of stroke was shown to decline to 68% by oral anticoagulant (OAC) therapy.The investigators have evaluated appropriate use of anticoagulants in non-valvular AF patients. Appropriate use of oral anticoagulants was assessed by Medication Appropriateness Index (MAI). The MAI consists of 10 criteias namely, indication, choice, dosage, modalities and practicability of administration, drug-drug interactions, drug-disease interactions, duplication, duration, and cost-effectiveness. The tenth criteria was not evaluated because of limited data regarding cost-effectiveness of the drugs.
Interventions
None listed
Sponsors
Muğla Sıtkı Koçman University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Non valbular AF \>18 years
Exclusion criteria
* Not currently receiving anticoagulant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients With at Least One Inappropriate MAI Criterion | 1 day | Appropriateness of oral anticoagulants was evaluated by adapted versions of the MAI |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Group 1 patients on warfarin therapy | 73 |
| Group 2 patients on rivaroxaban therapy | 39 |
| Group 3 Patients on dabigatran therapy | 36 |
| Total | 148 |
Baseline characteristics
| Characteristic | Group 1 | Group 2 | Group 3 | Total |
|---|---|---|---|---|
| Age, Continuous | 72 years STANDARD_DEVIATION 9 | 69 years STANDARD_DEVIATION 9 | 72 years STANDARD_DEVIATION 8 | 71 years STANDARD_DEVIATION 9 |
| Region of Enrollment Turkey | 73 participants | 39 participants | 36 participants | 148 participants |
| Sex: Female, Male Female | 42 Participants | 22 Participants | 20 Participants | 84 Participants |
| Sex: Female, Male Male | 31 Participants | 17 Participants | 16 Participants | 64 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 73 | 0 / 39 | 0 / 36 |
| serious Total, serious adverse events | 0 / 73 | 0 / 39 | 0 / 36 |
Outcome results
Primary
Number of Patients With at Least One Inappropriate MAI Criterion
Appropriateness of oral anticoagulants was evaluated by adapted versions of the MAI
Time frame: 1 day
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Group 1 | Number of Patients With at Least One Inappropriate MAI Criterion | 61 participants |
| Group 2 | Number of Patients With at Least One Inappropriate MAI Criterion | 11 participants |
| Group 3 | Number of Patients With at Least One Inappropriate MAI Criterion | 17 participants |